Halobetasol 0.01%/ tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: Maintenance of therapeutic effect after cessation of therapy

被引：0

作者：

Gold, Linda Stein ^{[1
]}

Kircik, Leon ^{[2
,3
,4
]}

Sugarman, Jeffrey ^{[5
]}

Lin, Tina ^{[6
]}

Pillai, Radhakrishnan ^{[7
]}

Varughese, Johnson ^{[7
]}

机构：

[1] Henry Ford Hosp, Detroit, MI 48202 USA

[2] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[3] Phys Skin Care PLLC, Louisville, KY USA

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Ortho Dermatol, Bridgewater, NJ USA

[7] Bausch Hlth, Bridgewater, NJ USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

9859

引用

页码：AB69 / AB69

页数：1

共 50 条

[31] Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne
Kircik, Leon H.
Lain, Edward
Gold, Michael
Katz, Bruce
Baldwin, Hilary
Guenin, Eric
Loncaric, Anya
Pillai, Radhakrishnan
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (11) : 1086 - 1092
[32] Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males
Cook-Bolden, Fran E.
Gold, Michael H.
Guenin, Eric
JOURNAL OF DRUGS IN DERMATOLOGY, 2020, 19 (01) : 78 - 85
[33] Safety and Efficacy of Halobetasol Propionate Lotion 0.01% in the Treatment of Moderate to Severe Plaque Psoriasis: A Pooled Analysis of 2 Phase 3 Studies
Sugarman, Jeffrey L.
Weiss, Jonathan S.
Tanghetti, Emil A.
Soung, Jennifer
Yamauchi, Paul S.
Lin, Tina
Harris, Susan
Martin, Gina
Pillai, Radhakrishnan
CUTIS, 2019, 103 (02): : 111 - +
[34] THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: A NETWORK META-ANALYSIS
Lozano-Ortega, G.
Rogula, B.
Gaudet, V
Mickle, A.
Johnston, K.
Barbeau, M.
VALUE IN HEALTH, 2019, 22 : S363 - S363
[35] An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis
Ozyurekoglu, Elif
Kircik, Leon H.
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (11) : 1191 - 1194
[36] Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
Green, Lawrence J.
Kerdel, Francisco A.
Cook-Bolden, Fran E.
Bagel, Jerry
Lin, Tina
Martin, Gina
Pillai, Radhakrishnan
Israel, Robert
Ramakrishna, Tage
JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1062 - 1069
[37] A CANADIAN NETWORK META-ANALYSIS OF THE EFFICACY OF HALOBETASOL PROPIONATE (0.01%) AND TAZAROTENE (0.045%) FIXED COMBINATION RELATIVE TO OTHER TOPICAL THERAPIES AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
Lozano-Ortega, G.
Rogula, B.
Gaudet, V
Mickle, A.
Johnston, K.
Barbeau, M.
VALUE IN HEALTH, 2020, 23 : S362 - S362
[38] Efficacy, safety and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of severe plaque psoriasis: Post hoc analysis of 2 phase III randomized controlled trials
Lebwohl, Mark G.
Sugarman, Jeffrey L.
Gold, Linda Stein
Lin, Tina
Harris, Susan
Desai, Chakshu
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB202 - AB202
[39] Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex
Green, Lawrence J.
Del Rosso, James Q.
Tanghetti, Emil A.
Guenin, Eric
JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (06) : 608 - 615
[40] A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast
Chiricozzi, Andrea
Caposiena, Dante
Garofalo, Virginia
Cannizzaro, Maria Vittoria
Chimenti, Sergio
Saraceno, Rosita
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (03) : 237 - 249

← 1 2 3 4 5 →